ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
profitability factor · long-only model fund

Foundry CBOperProf Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FCBOHYPOTHETICAL MODEL
Since ’99
+2927%
Expense Ratio
0.29%
placeholder
Holdings
214
cap-weighted
Inception
Feb 2019
placeholder
Full Sharpe
0.73
Ann. Return (LS)
14.3%
Ann. Volatility
19.5%
Max Drawdown
-43.2%
Test Sharpe ’19–26
0.83
Test FF5 α (ann.)
16.3%
vs Fama-French 5
Test FF5 α t-stat
2.91
significant (|t| ≥ 2)
Monthly turnover
10%
of the long leg, per rebalance
Cumulative return (LS)
2927%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.86
what this fund holds
Long leg ann. return
14.7%
buyable, long-only
Long-short Sharpe
0.73
requires shorting
Bottom bucket ann. return
0.4%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

214 of 214 · 100.0% of book
TickerCompanySectorMarket capWeight
1NVDA
NVIDIA CORPTechnology$4.91T
18.98%
2AAPL
APPLE INCTechnology$4.90T
18.96%
3GOOGL
ALPHABET INCCommunication Services$4.20T
16.25%
4AMZN
AMAZON COM INCConsumer Cyclical$2.66T
10.29%
5META
META PLATFORMS INCCommunication Services$1.64T
6.34%
6LLY
ELI LILLY & COHealthcare$1.11T
4.30%
7MU
MICRON TECHNOLOGY INCTechnology$958.80B
3.71%
8MA
MASTERCARD INCFinancial Services$480.32B
1.86%
9AMAT
APPLIED MATERIALS INCTechnology$420.53B
1.63%
10LRCX
LAM RESEARCH CORPTechnology$391.80B
1.52%
11MRK
MERCK & CO INCHealthcare$314.90B
1.22%
12KLAC
KLA CORPTechnology$277.91B
1.07%
13SNDK
SANDISK CORPTechnology$200.63B
0.78%
14QCOM
QUALCOMM INCTechnology$181.06B
0.70%
15STX
SEAGATE TECHNOLOGY HOLDINGS PLCTechnology$176.62B
0.68%
16GILD
GILEAD SCIENCES INCHealthcare$166.72B
0.64%
17WDC
WESTERN DIGITAL CORPTechnology$164.49B
0.64%
18APP
APPLOVIN CORPTechnology$142.62B
0.55%
19SCCO
SOUTHERN COPPER CORPBasic Materials$142.48B
0.55%
20BKNG
BOOKING HOLDINGS INCIndustrials$140.78B
0.54%
21BMY
BRISTOL MYERS SQUIBB COHealthcare$124.04B
0.48%
22VRTX
VERTEX PHARMACEUTICALS INCHealthcare$123.26B
0.48%
23SBUX
STARBUCKS CORPConsumer Cyclical$120.23B
0.47%
24ADBE
ADOBE INCTechnology$94.31B
0.36%
25DDOG
DATADOG INCTechnology$92.08B
0.36%
26CDNS
CADENCE DESIGN SYSTEMS INCTechnology$91.05B
0.35%
27HCA
HCA HEALTHCARE INCHealthcare$82.34B
0.32%
28REGN
REGENERON PHARMACEUTICALS INCHealthcare$70.94B
0.27%
29CIEN
CIENA CORPTechnology$53.00B
0.21%
30EA
ELECTRONIC ARTS INCCommunication Services$52.38B
0.20%
31ALAB
ASTERA LABS INCTechnology$52.04B
0.20%
32GRMN
GARMIN LTDTechnology$48.13B
0.19%
33ADSK
AUTODESK INCTechnology$46.07B
0.18%
34MSCI
MSCI INCFinancial Services$45.77B
0.18%
35IDXX
IDEXX LABORATORIES INCHealthcare$44.76B
0.17%
36RVMD
REVOLUTION MEDICINES INCHealthcare$39.58B
0.15%
37NTRA
NATERA INCHealthcare$38.87B
0.15%
38RBLX
ROBLOX CORPCommunication Services$37.02B
0.14%
39WDAY
WORKDAY INCTechnology$35.76B
0.14%
40ALNY
ALNYLAM PHARMACEUTICALS INCHealthcare$35.71B
0.14%
41RDDT
REDDIT INCCommunication Services$34.88B
0.13%
42ONC
BEONE MEDICINES LTDHealthcare$34.68B
0.13%
43UI
UBIQUITI INCTechnology$33.04B
0.13%
44DXCM
DEXCOM INCHealthcare$29.58B
0.11%
45FICO
FAIR ISAAC CORPTechnology$29.15B
0.11%
46ILMN
ILLUMINA INCHealthcare$28.24B
0.11%
47MTD
METTLER TOLEDO INTERNATIONAL INCHealthcare$26.47B
0.10%
48VRSK
VERISK ANALYTICS INCIndustrials$26.29B
0.10%
49VRSN
VERISIGN INCTechnology$25.27B
0.10%
50MDB
MONGODB INCTechnology$25.12B
0.10%
51TEAM
ATLASSIAN CORPTechnology$23.67B
0.09%
52INCY
INCYTE CORPHealthcare$23.42B
0.09%
53P
EVERPURE INCTechnology$23.06B
0.09%
54UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
0.09%
55NBIX
NEUROCRINE BIOSCIENCES INCHealthcare$17.18B
0.07%
56LSCC
LATTICE SEMICONDUCTOR CORPTechnology$17.16B
0.07%
57THC
TENET HEALTHCARE CORPHealthcare$16.79B
0.06%
58NTNX
NUTANIX INCTechnology$14.89B
0.06%
59DECK
DECKERS OUTDOOR CORPConsumer Cyclical$14.79B
0.06%
60LOGI
LOGITECH INTERNATIONAL SATechnology$14.76B
0.06%
61EXEL
EXELIXIS INCHealthcare$14.06B
0.05%
62PINS
PINTEREST INCCommunication Services$13.00B
0.05%
63GDDY
GODADDY INCTechnology$12.49B
0.05%
64NYT
NEW YORK TIMES COConsumer Cyclical$12.29B
0.05%
65HAS
HASBRO INCConsumer Cyclical$11.54B
0.04%
66HUBS
HUBSPOT INCTechnology$11.49B
0.04%
67PODD
INSULET CORPHealthcare$11.36B
0.04%
68RMBS
RAMBUS INCTechnology$10.97B
0.04%
69CART
INSTACART (MAPLEBEAR INC)Consumer Cyclical$10.77B
0.04%
70DPZ
DOMINOS PIZZA INCConsumer Cyclical$10.72B
0.04%
71ARWR
ARROWHEAD PHARMACEUTICALS INCHealthcare$10.47B
0.04%
72DOCU
DOCUSIGN INCTechnology$10.07B
0.04%
73CORT
CORCEPT THERAPEUTICS INCHealthcare$9.72B
0.04%
74MANH
MANHATTAN ASSOCIATES INCTechnology$9.66B
0.04%
75HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
0.04%
76MTCH
MATCH GROUP INCCommunication Services$9.13B
0.04%
77IONS
IONIS PHARMACEUTICALS INCHealthcare$8.99B
0.03%
78IMVT
IMMUNOVANT INCHealthcare$8.27B
0.03%
79ETSY
ETSY INCConsumer Cyclical$7.98B
0.03%
80MIRM
MIRUM PHARMACEUTICALS INCHealthcare$7.25B
0.03%
81SLAB
SILICON LABORATORIES INCTechnology$7.17B
0.03%
82DBX
DROPBOX INCTechnology$7.14B
0.03%
83CRUS
CIRRUS LOGIC INCTechnology$6.98B
0.03%
84SNDR
SCHNEIDER NATIONAL INCIndustrials$6.69B
0.03%
85MXL
MAXLINEAR INCTechnology$6.43B
0.02%
86APPF
APPFOLIO INCTechnology$6.36B
0.02%
87DUOL
DUOLINGO INCTechnology$6.24B
0.02%
88SEZL
SEZZLE INCFinancial Services$5.87B
0.02%
89QLYS
QUALYS INCTechnology$5.61B
0.02%
90TXG
10X GENOMICS INCHealthcare$5.55B
0.02%
91PEGA
PEGASYSTEMS INCTechnology$5.39B
0.02%
92KVYO
KLAVIYO INCTechnology$5.29B
0.02%
93TVTX
TRAVERE THERAPEUTICS INCHealthcare$5.27B
0.02%
94RELY
REMITLY GLOBAL INCTechnology$5.08B
0.02%
95KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL PLCHealthcare$4.92B
0.02%
96ACAD
ACADIA PHARMACEUTICALS INCHealthcare$4.38B
0.02%
97VKTX
VIKING THERAPEUTICS INCHealthcare$4.31B
0.02%
98CAKE
CHEESECAKE FACTORY INCConsumer Cyclical$4.26B
0.02%
99BOX
BOX INCTechnology$4.22B
0.02%
100PI
IMPINJ INCTechnology$4.21B
0.02%
101EXTR
EXTREME NETWORKS INCTechnology$3.97B
0.02%
102DOCS
DOXIMITY INCHealthcare$3.94B
0.02%
103CLBT
CELLEBRITE DI LTDTechnology$3.81B
0.01%
104ALMS
ALUMIS INCHealthcare$3.65B
0.01%
105NHC
NATIONAL HEALTHCARE CORPHealthcare$3.56B
0.01%
106RNG
RINGCENTRAL INCTechnology$3.46B
0.01%
107RCUS
ARCUS BIOSCIENCES INCHealthcare$3.44B
0.01%
108IDYA
IDEAYA BIOSCIENCES INCHealthcare$3.16B
0.01%
109CARG
CARGURUS INCConsumer Cyclical$3.16B
0.01%
110AGYS
AGILYSYS INCTechnology$3.00B
0.01%
111RARE
ULTRAGENYX PHARMACEUTICAL INCHealthcare$2.88B
0.01%
112ADEA
ADEIA INCTechnology$2.80B
0.01%
113CLDX
CELLDEX THERAPEUTICS INCHealthcare$2.77B
0.01%
114GPOR
GULFPORT ENERGY CORPEnergy$2.75B
0.01%
115AMBA
AMBARELLA INCTechnology$2.71B
0.01%
116GRND
GRINDR INCTechnology$2.71B
0.01%
117KOD
KODIAK SCIENCES INCHealthcare$2.67B
0.01%
118ALRM
ALARMCOM HOLDINGS INCTechnology$2.63B
0.01%
119CALX
CALIX INCTechnology$2.50B
0.01%
120CMPR
CIMPRESS PLCCommunication Services$2.49B
0.01%
121NRIX
NURIX THERAPEUTICS INCHealthcare$2.40B
0.01%
122BCRX
BIOCRYST PHARMACEUTICALS INCHealthcare$2.36B
0.01%
123BHVN
BIOHAVEN LTDHealthcare$2.32B
0.01%
124INTA
INTAPP INCTechnology$2.24B
0.01%
125CDNA
CAREDX INCHealthcare$2.05B
0.01%
126SNDX
SYNDAX PHARMACEUTICALS INCHealthcare$2.02B
0.01%
127HRMY
HARMONY BIOSCIENCES HOLDINGS INCHealthcare$1.96B
0.01%
128APPN
APPIAN CORPTechnology$1.92B
0.01%
129VRDN
VIRIDIAN THERAPEUTICS INCHealthcare$1.86B
0.01%
130SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
0.01%
131SONO
SONOS INCTechnology$1.80B
0.01%
132IMCR
IMMUNOCORE HOLDINGS PLCHealthcare$1.78B
0.01%
133ASAN
ASANA INCTechnology$1.77B
0.01%
134DV
DOUBLEVERIFY HOLDINGS INCTechnology$1.75B
0.01%
135ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.01%
136VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
0.01%
137NTLA
INTELLIA THERAPEUTICS INCHealthcare$1.59B
0.01%
138MLTX
MOONLAKE IMMUNOTHERAPEUTICSHealthcare$1.45B
0.01%
139ARLO
ARLO TECHNOLOGIES INCBasic Materials$1.45B
0.01%
140YELP
YELP INCCommunication Services$1.44B
0.01%
141AIP
ARTERIS INCTechnology$1.43B
0.01%
142WINA
WINMARK CORPConsumer Cyclical$1.39B
0.01%
143REAL
THEREALREAL INCConsumer Cyclical$1.35B
0.01%
144NVAX
NOVAVAX INCHealthcare$1.35B
0.01%
145DMLP
DORCHESTER MINERALS LPEnergy$1.31B
0.01%
146HLIT
HARMONIC INCTechnology$1.31B
0.01%
147XNCR
XENCOR INCHealthcare$1.30B
0.01%
148NSSC
NAPCO SECURITY TECHNOLOGIES INCIndustrials$1.29B
0.00%
149INBX
INHIBRX BIOSCIENCES INCHealthcare$1.28B
0.00%
150LQDT
LIQUIDITY SERVICES INCConsumer Cyclical$1.23B
0.00%
151CBRL
CRACKER BARREL OLD COUNTRY STORE INCConsumer Cyclical$1.20B
0.00%
152HTLD
HEARTLAND EXPRESS INCIndustrials$1.19B
0.00%
153MGTX
MEIRAGTX HOLDINGS PLCHealthcare$1.15B
0.00%
154CRTO
CRITEO SACommunication Services$1.13B
0.00%
155UPWK
UPWORK INCIndustrials$1.12B
0.00%
156EYPT
EYEPOINT INCHealthcare$1.12B
0.00%
157FBRX
FORTE BIOSCIENCES INCHealthcare$1.00B
0.00%
158VOR
VOR BIOPHARMA INCHealthcare$980M
0.00%
159ANNX
ANNEXON INCHealthcare$950M
0.00%
160EVER
EVERQUOTE INCCommunication Services$925M
0.00%
161TDUP
THREDUP INCConsumer Cyclical$852M
0.00%
162DSP
VIANT TECHNOLOGY INCTechnology$754M
0.00%
163RIGL
RIGEL PHARMACEUTICALS INCHealthcare$750M
0.00%
164AURA
AURA BIOSCIENCES INCHealthcare$723M
0.00%
165CARS
CARSCOM INCConsumer Cyclical$670M
0.00%
166PHR
PHREESIA INCHealthcare$662M
0.00%
167MNTN
MNTN INCTechnology$661M
0.00%
168NRDS
NERDWALLET INCCommunication Services$609M
0.00%
169FDMT
4D MOLECULAR THERAPEUTICS INCHealthcare$575M
0.00%
170OOMA
OOMA INCCommunication Services$568M
0.00%
171NPCE
NEUROPACE INCHealthcare$548M
0.00%
172YEXT
YEXT INCTechnology$535M
0.00%
173ARVN
ARVINAS INCHealthcare$517M
0.00%
174RGNX
REGENXBIO INCHealthcare$511M
0.00%
175NVCT
NUVECTIS PHARMA INCHealthcare$508M
0.00%
176DCTH
DELCATH SYSTEMS INCHealthcare$442M
0.00%
177PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.00%
178RLGT
RADIANT LOGISTICS INCIndustrials$431M
0.00%
179SGU
STAR GROUP LPEnergy$430M
0.00%
180CBIO
CRESCENT BIOPHARMA INCHealthcare$407M
0.00%
181ENTA
ENANTA PHARMACEUTICALS INCHealthcare$400M
0.00%
182NATH
NATHANS FAMOUS INCConsumer Cyclical$393M
0.00%
183STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.00%
184CRNC
CERENCE INCTechnology$390M
0.00%
185UPB
UPSTREAM BIO INCHealthcare$382M
0.00%
186NATR
NATURES SUNSHINE PRODUCTS INCConsumer Defensive$359M
0.00%
187PLAY
DAVE & BUSTER'S ENTERTAINMENT INCCommunication Services$355M
0.00%
188XPER
XPERI INCTechnology$352M
0.00%
189CV
CAPSOVISION INCHealthcare$335M
0.00%
190BKKT
BAKKT INCTechnology$323M
0.00%
191MKTW
MARKETWISE INCTechnology$314M
0.00%
192FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
0.00%
193QTTB
Q32 BIO INCHealthcare$255M
0.00%
194ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.00%
195GLSI
GREENWICH LIFESCIENCES INCHealthcare$240M
0.00%
196SPOK
SPOK HOLDINGS INCHealthcare$222M
0.00%
197KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.00%
198AGEN
AGENUS INCHealthcare$209M
0.00%
199DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.00%
200EGAN
EGAIN CORPTechnology$180M
0.00%
201ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.00%
202CRBP
CORBUS PHARMACEUTICALS HOLDINGS INCHealthcare$167M
0.00%
203PMN
PROMIS NEUROSCIENCES INCHealthcare$136M
0.00%
204VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.00%
205AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.00%
206CUE
CUE BIOPHARMA INCHealthcare$126M
0.00%
207INSG
INSEEGO CORPTechnology$122M
0.00%
208SOTK
SONO TEK CORPTechnology$86M
0.00%
209CSBR
CHAMPIONS ONCOLOGY INCHealthcare$85M
0.00%
210ACET
ADICET BIO INCHealthcare$76M
0.00%
211ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.00%
212BODI
BEACHBODY COMPANY INCCommunication Services$75M
0.00%
213BGSF
BGSF INCIndustrials$65M
0.00%
214XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $25.85T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

9 sectors
Technology
52.6%
Communication Services
23.2%
Consumer Cyclical
11.1%
Healthcare
9.8%
Financial Services
2.1%
Industrials
0.7%
Basic Materials
0.6%
Energy
0.0%
Consumer Defensive
0.0%

Portfolio Style

Size × value map of the long-leg book

214 classified
Value
Blend
Growth
Large
Mid
Small
1%7
26%30
72%52
<1%8
<1%21
<1%30
<1%22
<1%13
<1%12

Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 100% toward Large, 85% toward Growth. Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt100% → Large
SmallLarge
Value ↔ growth tilt85% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 214 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
3
Failed
2
Not tested
2
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    54.2%
    Margin
    -20.8%
  • The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).

    Required
    <= 25.0%
    Actual
    28.4%
    Margin
    -3.4%
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 214 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.1 (95% CI 0.8-1.3)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
10.2%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.06x
within
parametric
1.04x
within
cornish fisher
0.93x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2016
Before publication (pre-2016)
0.60
Sharpe · 11.2% p.a.
January 1999December 2016 · 216 mo
Since publication
0.96
Sharpe · 20.0% p.a.
January 2017July 2026 · 115 mo
Change in Sharpe+0.37Sharpe strengthened since publication79% stronger in annual return

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
81%
21 of 26 3-year windows made money
Worst window
-0.90
Sharpe, January 2003 – December 2005
January 1999July 2026
Median Sharpe
0.83
Dispersion
0.71
Best window
1.80

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.28.6%19.8%
3 yearsp.a.27.7%21.3%
5 yearsp.a.18.4%26.2%
10 yearsp.a.21.8%18.8%
Since inceptionp.a.14.1%13.2%
Calendar years
YearLong legLong-short
20267 mo10.4%5.1%
202525.1%8.2%
202442.0%36.5%
202357.2%28.8%
2022-31.5%23.9%
202130.5%42.0%
202042.0%-4.0%
201932.6%2.0%
20182.4%24.3%
201734.2%28.6%
20165.3%4.1%
20159.9%17.8%
201417.8%17.6%
201343.8%9.5%
201215.7%-3.9%
20112.6%11.7%
201010.3%-12.7%
200937.0%-15.3%
2008-27.9%54.5%
200711.4%1.8%
200611.1%0.2%
20056.9%2.5%
20044.4%-14.0%
200322.0%-19.0%
2002-20.2%38.7%
2001-13.4%31.4%
200016.6%136.8%
199954.4%-9.5%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FCBO
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.29% (placeholder)
Inception2019-02-22 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$25.85T

Methodology

The Foundry CBOperProf Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks (price > $5, market-cap floor) each month by a CBOperProf signal and holds the top decile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.